The impact of generic reference pricing in Italy, a decade on
- 434 Downloads
The generic reference price (GRP) was introduced in Italy in 2001. The main purpose of this paper is: (a) producing evidence regarding the effect of GRP on prices; (b) testing the hypothesis that there is a reallocation of demand from the genericated (and reference-priced) molecules to patent-protected products that have the same therapeutic indication.
The analysis used a unique dataset of quantities and revenues of six therapeutic groups that were observed for more than a decade. Difference-in-differences analysis is applied. Prices are adjusted for all the regulatory interventions in the ten years of observations, to control for confounding impact of these interventions.
On average, prices dropped 13 % more in groups to which GRP was applied than in other groups. Moreover, each entry of a new generic was associated with a price drop of around 2.8 %. On the other hand, GRP did not induce any significant switching towards in-patent molecules.
We provide the first empirical results of the impact of GRP on prices in Italy and evidence that GRP cannot be held solely responsible for the often reported demand reallocation towards new and in-patent molecules.
KeywordsPolicy impact Pharmaceutical policy Reference pricing Italy
JEL ClassificationI18 L51
- 1.OECD: OECD Health Data 2012. http://stats.oecd.org/Index.aspx?DataSetCode=SHA (2012). Accessed 6 Feb 2012
- 3.Jommi, C., Armeni, P., De Luca, C., et al.: Il governo regionale dell’assistenza farmaceutica e il suo impatto sulla spesa. In: Cantù, E. (ed.) Rapporto OASI 2011, L’aziendalizzazione della sanità italiana, pp. 259–296. Egea, Milano (2011)Google Scholar
- 7.Danzon, P., Liu, H.: Reference Pricing and Physician Drug Budgets: The German Experience in Controlling Pharmaceutical Expenditures. Working Paper. The Wharton School, Philadelphia (1997)Google Scholar
- 9.Brekke, K.R., Holmas, T.H., Straume, O.R.: Reference pricing, competition, and pharmaceutical expenditures: theory and evidence from a natural experiment. J. Pub. Econ. 95, 626–638 (2011)Google Scholar
- 17.The World Health Organization (WHO) Collaborating Centre for Drugs Statistics Methodology: ATC/DDD Index 2009. http://www.whocc.no/atc_ddd_index (2009). Accessed 30 Nov 2009
- 18.AIFA (Agenzia Italiana del Farmaco): L’uso dei farmaci in Italia: rapporto nazionale, Anno 2009, Rapporto OSMED. Il Pensiero Scientifico Ed, Roma (2010)Google Scholar